The primary target audiences for this educational activity include internal medicine/family medicine/primary care providers (MDs, NPs, PAs), endocrinologists, cardiologists, and other HCPs who manage people with obesity/metabolic syndrome who are at risk for severe acute and long-term complications from COVID-19.
The goal of this activity is to improve HCPs’ awareness of the risk of acute and long-term complications of COVID-19 in people with obesity and/or metabolic syndrome and to increase HCPs’ competence in appropriate management and prevention of acute and long COVID-19 in this population.
Upon completion of this activity, participants should be able to:
Counsel people with obesity and/or metabolic syndrome on the risks associated with severe acute and postacute COVID-19 outcomes
Select the most appropriate prevention and treatment strategies for COVID-19 in ambulatory patients with obesity and/or metabolic syndrome
Incorporate strategies aimed at reducing the impact of healthcare disparities in the prevention and treatment of people with obesity/metabolic syndrome and COVID-19
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Rasika Karnik, MS, MD
Division of Primary Care, Department of Internal Medicine
University of Chicago
Post-Covid Recovery Clinic
Rasika Karnik, MS, MD: consultant/advisor/speaker: Gilead Sciences.
Donna H. Ryan, MD
Pennington Biomedical Research Center
New Orleans, Louisiana
Donna Ryan, MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Renslow Sherer, MD: researcher: Gilead.
The planners and content peer reviewers from Clinical Care Options, LLC and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from September 19, 2023, through September 18, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hour awarded for this Nursing Continuing Professional Development activity is 1 contact hour.